Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | SRC | P12931 | 6/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611617 | 0.91 | CDK4 (0.45) | KDRSRCRIPK2ACVR1NOD2 | |
| SCHEMBL3599596 | 0.84 | KDR (0.46) | KDRSRCRIPK2ACVR1NOD2 | |
| SCHEMBL3605827 | 0.81 | KDR (0.43) | KDRCHEK1CDK4CCND1CCND2 | |
| SCHEMBL3595740 | 0.80 | MCHR1 (0.42) | KDRCDK4CCND1CCND2CCND3 | |
| SCHEMBL13605374 | 0.79 | CDK4 (0.51) | KDRSRCRIPK2ACVR1NOD2 | |
| SCHEMBL3602411 | 0.78 | KDR (0.53) | KDRFGFR1MAPK14 | |
| SCHEMBL3603529 | 0.78 | KDR (0.49) | KDRCHEK1HRH3FLT1 | |
| SCHEMBL3610222 | 0.78 | LMNA (0.36) | KDRESR1HRH3LCK | |
| SCHEMBL3607653 | 0.74 | RIPK2 (0.54) | KDRSRCRIPK2ACVR1NOD2 | |
| SCHEMBL3596601 | 0.74 | MAPKAPK2 (0.55) | KDRCHEK1CDK4CCND1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | claimed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | claimed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | KDR 8/4885SRC 38/4885RIPK2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.